The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...

Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...

Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and ...

Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday.

Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...

As we continue to make progress on increasing supply for Wegovy ® (WegovySupply.com) to meet continued demand, Novo Nordisk is equally focused on reinforcing the U.S. Food and Drug Administration (FDA ...

In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...

Structure's once-daily oral drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk's blockbuster weight-loss drug Wegovy and Eli Lilly's Zepbound. Leerink analysts said in a note ...